Lysogene S.A.

Plus: New CEOs at Alchemab and Genespire, and more from Leyden and Pharmazz

Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model 

At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA

Plus: Apellis shares bounce as FDA accepts amended NDA, and updates from Iovance, RAPT, G1, Lysogene and RongCan

The fragile X pipeline comprises as many drugs targets as drug candidates

Plus BMS-Prellis, Lysogene-Sarepta, Biohaven-KU Leuven, Castle Creek-Novavita and Idorsia

More than half of clinical AAV programs target neurology and ophthalmic conditions